EA201992326A1 - Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака - Google Patents
Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов ракаInfo
- Publication number
- EA201992326A1 EA201992326A1 EA201992326A EA201992326A EA201992326A1 EA 201992326 A1 EA201992326 A1 EA 201992326A1 EA 201992326 A EA201992326 A EA 201992326A EA 201992326 A EA201992326 A EA 201992326A EA 201992326 A1 EA201992326 A1 EA 201992326A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- stem cells
- methods
- cancer
- csc
- compositions
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 210000000130 stem cell Anatomy 0.000 title abstract 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 title abstract 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002540 macrophage Anatomy 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479768P | 2017-03-31 | 2017-03-31 | |
| PCT/US2018/025470 WO2018183894A1 (en) | 2017-03-31 | 2018-03-30 | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992326A1 true EA201992326A1 (ru) | 2020-03-13 |
Family
ID=63676868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992326A EA201992326A1 (ru) | 2017-03-31 | 2018-03-30 | Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200109205A1 (OSRAM) |
| EP (2) | EP4353318A3 (OSRAM) |
| JP (2) | JP2020512978A (OSRAM) |
| KR (1) | KR102630070B1 (OSRAM) |
| CN (1) | CN110662559A (OSRAM) |
| AU (1) | AU2018243670B2 (OSRAM) |
| BR (1) | BR112019020451A2 (OSRAM) |
| CA (1) | CA3058458A1 (OSRAM) |
| EA (1) | EA201992326A1 (OSRAM) |
| IL (1) | IL269746A (OSRAM) |
| MX (1) | MX2019011717A (OSRAM) |
| WO (1) | WO2018183894A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12383634B2 (en) | 2019-07-24 | 2025-08-12 | Korea Basic Science Institute | Single domain antibody targeting αVβ3 integrin |
| US20210032348A1 (en) * | 2019-08-02 | 2021-02-04 | The Regents Of The University Of California | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers |
| CA3172092A1 (en) * | 2020-04-23 | 2021-10-28 | David Cheresh | Compositions and methods for treating cancer |
| CN112626118B (zh) * | 2020-11-12 | 2023-06-23 | 清华-伯克利深圳学院筹备办公室 | 细胞株及其应用 |
| CN118284622A (zh) * | 2021-09-30 | 2024-07-02 | 阿尔法贝塔控股有限责任公司 | 治疗癌症的组合物和方法 |
| CN115960160B (zh) * | 2021-10-12 | 2024-07-16 | 南京大学 | 活细胞膜整合素αvβ3聚糖的原位糖链延长方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
| RU2194528C2 (ru) * | 1996-05-31 | 2002-12-20 | Дзе Скриппс Рисерч Инститьют | Способы и композиции, используемые для ингибирования ангиогенеза |
| US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| CN1261791A (zh) | 1997-07-02 | 2000-08-02 | Sdg有限公司 | 诊断或治疗用途的靶向脂质体构建物 |
| EP1156823B1 (en) | 1999-02-12 | 2008-10-29 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| JP4111368B2 (ja) | 1999-04-23 | 2008-07-02 | 三菱化学株式会社 | 抗体およびポリアルキレングリコール結合リポソーム |
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US7858117B2 (en) | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| EP1487492A4 (en) * | 2002-03-04 | 2008-10-01 | Medimmune Inc | PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS COMBINED WITH OTHER AGENTS |
| EP1547581A1 (en) | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
| CA2549966A1 (en) | 2003-12-24 | 2005-07-07 | Ltt Bio-Pharma Co., Ltd. | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| EP1722762A2 (en) | 2004-03-02 | 2006-11-22 | Massachusetts Institute of Technology | Nanocell drug delivery system |
| EP1773298A1 (en) | 2004-08-06 | 2007-04-18 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
| CA2577370A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| DK1896071T3 (en) * | 2005-06-30 | 2015-05-26 | Janssen Biotech Inc | Methods and compositions with increased therapeutic activity |
| AU2006274413B2 (en) | 2005-07-27 | 2013-01-10 | Arbutus Biopharma Corporation | Systems and methods for manufacturing liposomes |
| US20080088046A1 (en) | 2006-10-13 | 2008-04-17 | Steffen Panzner | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| US7928113B2 (en) * | 2005-11-14 | 2011-04-19 | University Of Southern California | Integrin-binding small molecules |
| US20080089928A1 (en) | 2006-06-13 | 2008-04-17 | Stavroula Sofou | Liposome drug carriers with ph-sensitivity |
| US20110319335A1 (en) * | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| US20140154264A1 (en) * | 2011-06-02 | 2014-06-05 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition |
| WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| CN106232625B (zh) * | 2013-10-01 | 2020-04-24 | 免疫医疗有限公司 | 治疗和诊断过表达α-V-β-6的癌症的方法 |
| CN105940107B (zh) * | 2013-11-11 | 2021-06-15 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
| WO2016100858A1 (en) | 2014-12-18 | 2016-06-23 | The Regents Of The University Of California | Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype |
| US20210032348A1 (en) * | 2019-08-02 | 2021-02-04 | The Regents Of The University Of California | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers |
-
2018
- 2018-03-30 KR KR1020197031332A patent/KR102630070B1/ko active Active
- 2018-03-30 AU AU2018243670A patent/AU2018243670B2/en active Active
- 2018-03-30 CA CA3058458A patent/CA3058458A1/en active Pending
- 2018-03-30 EP EP23203602.0A patent/EP4353318A3/en active Pending
- 2018-03-30 CN CN201880033739.9A patent/CN110662559A/zh active Pending
- 2018-03-30 WO PCT/US2018/025470 patent/WO2018183894A1/en not_active Ceased
- 2018-03-30 JP JP2019553167A patent/JP2020512978A/ja active Pending
- 2018-03-30 BR BR112019020451A patent/BR112019020451A2/pt unknown
- 2018-03-30 MX MX2019011717A patent/MX2019011717A/es unknown
- 2018-03-30 EP EP18774300.0A patent/EP3600422B1/en active Active
- 2018-03-30 US US16/499,623 patent/US20200109205A1/en not_active Abandoned
- 2018-03-30 EA EA201992326A patent/EA201992326A1/ru unknown
-
2019
- 2019-10-02 IL IL26974619A patent/IL269746A/en unknown
-
2021
- 2021-03-29 JP JP2021054730A patent/JP2021095423A/ja active Pending
-
2023
- 2023-10-04 US US18/480,778 patent/US20240067733A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3600422B1 (en) | 2023-10-18 |
| EP4353318A2 (en) | 2024-04-17 |
| BR112019020451A2 (pt) | 2020-04-28 |
| KR102630070B1 (ko) | 2024-01-26 |
| US20200109205A1 (en) | 2020-04-09 |
| EP4353318A3 (en) | 2024-07-17 |
| IL269746A (en) | 2019-11-28 |
| AU2018243670A1 (en) | 2019-10-31 |
| JP2020512978A (ja) | 2020-04-30 |
| MX2019011717A (es) | 2019-12-16 |
| KR20190133205A (ko) | 2019-12-02 |
| JP2021095423A (ja) | 2021-06-24 |
| EP3600422A4 (en) | 2021-01-13 |
| CN110662559A (zh) | 2020-01-07 |
| AU2018243670B2 (en) | 2025-05-01 |
| WO2018183894A1 (en) | 2018-10-04 |
| CA3058458A1 (en) | 2018-10-04 |
| US20240067733A1 (en) | 2024-02-29 |
| EP3600422A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992326A1 (ru) | Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака | |
| EA201691747A1 (ru) | Варианты комбинированной терапии с антителами анти-cd38 | |
| CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| MX2024015844A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
| MX2018014950A (es) | Terapia de combinacion. | |
| EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
| PH12022550509A1 (en) | Anti-cd73 antibodies | |
| EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
| TN2016000142A1 (en) | Specific anti-cd38 antibodies for treating human cancers. | |
| PH12020550035A1 (en) | Universal abt compounds and uses thereof | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| WO2019112347A3 (ko) | 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도 | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
| EA202092518A1 (ru) | Композиции и способы лечения рака | |
| ZA202302392B (en) | Antibodies against ilt2 and use thereof | |
| MX2024007390A (es) | Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo. | |
| WO2019089753A3 (en) | Cd137 antibodies and pd-1 antagonists and uses thereof | |
| MX2022005816A (es) | Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70. | |
| PH12022550006A1 (en) | Cd38-binding agents and uses thereof | |
| MX2024003779A (es) | Agentes de union dirigidos a celulas tumorales que expresan trop2. | |
| EA201491352A1 (ru) | Способ лечения рака груди | |
| PH12016500677A1 (en) | Specific anti-cd38 antibodies for treating human cancers |